Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for its first-in-class CDK 4/6 inhibitor, IBRANCE® (palbociclib).
You are here
Press Release Archive
Pfizer Inc. (NYSE:PFE) announced today the European Commission (EC) has approved an expanded indication for Nimenrix™ (meningococcal group A, C, W-135, and Y conjugate vaccine) for active immunization against invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135, and Y (MenACWY) in infants as early as six weeks of age. Nimenrix is now the first and only MenACWY conjugate vaccine in the European Union (EU) that can be administered from six weeks of age with no upper age limit.
Pfizer announced today that the U.S.
Pfizer Inc. (NYSE:PFE) announced today that the U.S.
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503) today announced the Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with XTANDI® (enzalutamide), plus abiraterone acetate and prednisone as compared to treatment with abiraterone acetate and prednisone alone, did not meet its primary endpoint of improvement in progression-free survival (PFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (CRPC) whose prostate-specific antigen (PSA) has previously progressed on XTANDI.
NEW YORK, N.Y., December 14 – Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) approved EUCRISA™ (crisaborole) ointment, 2%.
Please see full Prescribing Information at www.pfizer.com.
The board of directors of Pfizer Inc. today declared a 32-cent first-quarter 2017 dividend on the company’s common stock, payable March 1, 2017, to shareholders of record at the close of business on February 3, 2017. Pfizer increased the dividend by approximately 7 percent, to 32 cents from 30 cents per share.
Pfizer Inc. (NYSE:PFE) today announced that it will expand the company’s Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) program in 2017 to award up to $5.5 million (USD) in new competitive grants to fund research studies involving Pfizer products in both breast and hematologic cancers. This expanded program will be known as the ASPIRE Oncology/Hematology Clinical Research Awards.
Today, Pfizer Inc. and its partner Avillion LLP announced results from the Phase 3 BFORE (Bosutinib trial in First line chrOnic myelogenous leukemia tREatment) trial demonstrating superiority of BOSULIF® (bosutinib) over imatinib as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). The study met its primary endpoint of major molecular response (MMR) at 12 months.
Today, Pfizer Inc.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Citi 2016 Global Healthcare Conference on Thursday, December 8, 2016 at 2:10 p.m. Eastern Standard Time.
Pfizer Inc. (NYSE:PFE) announced today positive top-line results of a study that evaluated the use of LYRICA® (pregabalin) Capsules CV and Oral Solution CV as adjunctive therapy for pediatric epilepsy patients four to 16 years of age with partial onset seizures. Results showed that adjunctive treatment with LYRICA 10 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo, the primary efficacy endpoint. Treatment with LYRICA 2.5 mg/kg/day resulted in a numerical reduction in seizure frequency, which was not statistically significant.
Pfizer Inc. (NYSE:PFE) today announced that the pivotal REFLECTIONS B3271002 study, a comparative safety and efficacy study of PF-05280014 versus Herceptin® (trastuzumab), met its primary endpoint. PF-05280014 is being developed by Pfizer as a potential biosimilar to Herceptin.
EMD Serono Inc., the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada
Pfizer Inc. (NYSE:PFE) today announced that Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply will retire from the company after more than 41 years with Pfizer.
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.